https://www.selleckchem.com/products/actinomycin-d.html Type 1 diabetes is the most common type of diabetes among children and young people, and requires careful management to ensure that blood glucose levels stay as close as possible to the target range. Suboptimal management can lead to serious health consequences, including damage to various organs and body systems. Many children with type 1 diabetes are not diagnosed until they develop diabetic ketoacidosis, which is distressing and potentially life-threatening. This article provides an overview of the management of type 1 diabetes in children and young people, including the insulin replacement therapy and dietary management required. It also emphasises the importance of regular and ongoing monitoring of blood glucose levels, quarterly measurement of glycated haemoglobin, and the management of hyperglycaemia and hypoglycaemia. Medical devices intended for weight loss may provide clinically meaningful benefit to children who are overweight and have obesity; however, no device has been approved by the U.S. Food and Drug Administration (FDA) for use in patients below 18 years of age. Encouragingly, FDA regularly sees new device designs because the field of weight-loss devices is advancing rapidly. As more devices for weight loss are in development, their use in adolescent populations is expected to follow, but supporting data are needed. This report describes efforts that FDA has taken to understand the unmet clinical need, understand how pediatric patients might benefit from a weight-loss device, and provide considerations for how to best design weight-loss device clinical studies considering device-specific patient risk for adolescents. We review the recommendations provided to the FDA in 2005 via a Pediatric Advisory Committee meeting and discuss feedback received in 2018 through our Network of Experts programme. FDA encourages weight-loss device manufacturers and academic researchers to collect data through pro